Cencora Earnings Reports

Cencora reported a strong start to fiscal year 2025, with revenue increasing by 12.8% year-over-year to $81.5 billion. GAAP diluted EPS was $2.50, while adjusted diluted EPS increased by 13.7% to $3.73. The company has raised its adjusted diluted EPS guidance for fiscal year 2025 to a range of $15.25 to $15.55.

Cencora's fiscal 2024 fourth quarter saw a significant revenue increase of 14.7% to $79.1 billion. GAAP diluted EPS was $0.02, while adjusted diluted EPS rose by 16.8% to $3.34. The company also announced an 8% increase in its quarterly dividend.

Cencora reported a strong third quarter in fiscal year 2024, with revenue reaching $74.2 billion, a 10.9% increase year-over-year. Adjusted diluted EPS increased by 14.4% to $3.34. The company has raised its fiscal year 2024 adjusted diluted EPS guidance to a range of $13.55 to $13.65.

Cencora reported a strong second quarter with revenue increasing by 7.8% year-over-year to $68.4 billion. GAAP diluted EPS was $2.09, while adjusted diluted EPS increased by 8.6% to $3.80. The company raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.30 to $13.50.

Cencora's first quarter fiscal year 2024 showed strong performance with a 15.0% increase in revenue to $72.3 billion. GAAP diluted EPS was $2.98, while adjusted diluted EPS increased to $3.28. The company has raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.25 to $13.50.

Cencora reported a 12.7% increase in revenue to $68.9 billion for Q4 2023. GAAP diluted EPS was $1.72, while adjusted diluted EPS increased by 10.0% to $2.86. The company's U.S. Healthcare Solutions and International Healthcare Solutions segments both contributed to the revenue growth.

Cencora reported a strong Q3 2023 with revenue reaching $66.9 billion, an 11.5% increase year-over-year. GAAP diluted EPS was $2.35, and adjusted diluted EPS was $2.92. The company raised its adjusted diluted EPS guidance for fiscal year 2023 to a range of $11.85 to $11.95.

AmerisourceBergen Corporation's Q2 2023 earnings showcased a robust 9.9% increase in revenue, reaching $63.5 billion. Adjusted diluted EPS grew by 8.7% to $3.50, reflecting the company's strong financial performance and strategic execution. The company raised its full-year financial outlook, demonstrating the value of its pharmaceutical-centric strategy and key strategic partnerships.

AmerisourceBergen reported a solid first quarter with a 5.4% increase in revenue to $62.8 billion. GAAP diluted EPS was $2.33, and adjusted diluted EPS increased by 5.0% to $2.71. The company raised its adjusted diluted EPS guidance for fiscal year 2023 to $11.50 to $11.75.

AmerisourceBergen Corporation reported a 3.8% increase in revenue for the fourth quarter of fiscal year 2022, reaching $61.2 billion. GAAP diluted EPS was $1.40, while adjusted diluted EPS increased by 8.8% to $2.60. The company's performance was driven by growth in U.S. Healthcare Solutions, offset by a decrease in International Healthcare Solutions due to foreign currency translation.

AmerisourceBergen reported a strong third quarter with revenue increasing by 12.5% year-over-year to $60.1 billion. The company raised its full year outlook for adjusted diluted EPS to a range of $10.90 to $11.10.

AmerisourceBergen reported a strong second quarter with revenue increasing by 17.4% year-over-year to $57.7 billion. GAAP diluted EPS was $2.59, and adjusted diluted EPS increased by 27.3% to $3.22. The company also raised its adjusted diluted EPS guidance for fiscal year 2022 to a range of $10.80 to $11.05.

AmerisourceBergen reported a strong first quarter with revenue increasing by 13.5% year-over-year to $59.6 billion. Adjusted diluted EPS increased by 18.3% to $2.58. The company has raised its adjusted diluted EPS guidance for fiscal year 2022 to a range of $10.60 to $10.90.

AmerisourceBergen's Q4 2021 revenue increased by 19.6% to $58.9 billion. GAAP diluted EPS was $2.08, while adjusted diluted EPS increased by 26.5% to $2.39. The company's performance was driven by growth in Pharmaceutical Distribution Services and the acquisition of Alliance Healthcare.

AmerisourceBergen Corporation reported a 17.7% increase in revenue to $53.4 billion for the third quarter of fiscal year 2021. The company's GAAP diluted EPS was $1.40, while adjusted diluted EPS increased to $2.16. The company has raised its adjusted diluted EPS guidance for fiscal year 2021 to a range of $9.15 to $9.30.

AmerisourceBergen reported a solid performance in the March quarter, with revenue increasing by 3.7% year-over-year to $49.2 billion. The company's adjusted diluted EPS increased by 5.4% to $2.53, and the adjusted diluted EPS guidance for fiscal year 2021 has been raised to a range of $8.45 to $8.60.

AmerisourceBergen reported a strong first quarter in fiscal year 2021, with revenue increasing by 9.7% year-over-year to $52.5 billion. GAAP diluted EPS was $1.81, and adjusted diluted EPS increased by 24% to $2.18. The company raised its adjusted diluted EPS guidance for fiscal year 2021 to a range of $8.40 to $8.60.

AmerisourceBergen Corporation reported a 7.9% increase in revenue to $49.2 billion for the fourth quarter of fiscal year 2020. GAAP diluted EPS was $(23.74), while adjusted diluted EPS increased 17.4% to $1.89. The company recorded a $6.6 billion expense accrual related to opioid lawsuits.

AmerisourceBergen reported a slight increase in revenue for Q3 2020, with a rise in adjusted diluted EPS. The company raised its adjusted diluted EPS guidance for fiscal year 2020.

AmerisourceBergen reported a 9.5% increase in revenue to $47.4 billion for the second quarter of fiscal year 2020. GAAP diluted EPS was $4.64, while adjusted diluted EPS increased by 13.7% to $2.40. The company has revised its adjusted diluted EPS guidance for fiscal year 2020 to $7.35 to $7.65.

AmerisourceBergen reported a strong first quarter in fiscal year 2020, with revenue reaching $47.9 billion, a 5.4% increase year-over-year. Adjusted diluted EPS grew by 10.0% to $1.76. The company has raised its adjusted diluted EPS guidance range for fiscal year 2020 to $7.55 to $7.80. The Board of Directors also increased the quarterly dividend rate by 5% to $0.42 per share.